Merck & Co postpones closures
“U.S. drugmaker Merck & Co postponed on Thursday the planned closures of some Dutch operations announced in July while it negotiates with executives and workers on potential alternatives. The last-minute deal averts a court hearing that had been scheduled for Thursday afternoon, at which employees of the Dutch unit, formerly called [...]
From our Friends at LCGC…Their latest Tweet!
A tweet on New Horizons in Reversed-Phase Chromatography http://ow.ly/2iJz3
“In the latest LCGC North America high performance liquid chromatography (HPLC) column survey (1), over 95% of all respondents used reversed-phase chromatography in their daily work. The popularity of this technique is undoubtedly due to its versatility. Reversed-phase chromatography can separate [...]
Senior Medical Writer – Medical Communications – London
As pharmaceutical scientists in today’s economy, we are often challenged to expand our scope. It the past we pigeonholed ourselves into lab only type carrers. Opportunities that one may have passed up in 2005 are now considered. Scientific writers are a rare breed. One who has a mind for science and a flair for communication. [...]
Astellas Pharma Closing Two N.Y. Facilities By June 2011
“Astellas Pharma Inc. is planning to close two facilities in New York that had been operated by OSI Pharmaceuticals Inc., which the Japanese drug maker bought for $4 billion in June. An Astella spokeswoman said that OSI’s Ardsley and Melville facilities will close by June 2011, affecting about 150 workers at those sites…more“
AstraZeneca Hopeful for Positive FDA Call on Blood-Thinner but Doubts Linger
“An FDA advisory committee’s strong vote in favor of AstraZeneca’s (AZN) blood-thinner Brilinta was tempered by long-held concerns over the failure of the drug’s pivotal trial to show a survival benefit in the US population when compared to Plavix (Event – Brilinta has questions to answer, July 21, 2010). With adcom members raising concerns over [...]
Sanofi fights FDA approval of generic Lovenox
“The FDA has approved the first generic version of the blockbuster low molecular weight heparin Lovenox (enoxaparin sodium), much to originator sanofi-aventis’s displeasure. Sanofi has expressed concerns about the generic’s safety and, according to a report from Reuters, has even asked a court to block the approval, claiming that the FDA’s decision was “arbitrary and [...]
keep looking »
